The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
NCRI 2016 | Overview of the PD-1/PD-L1 research presentation
Lieping Chen, MD, PhD of Yale School of Medicine, New Haven, CT gives an overview of his talk on PD-1/PD-L1 molecular pathway research. For almost 20 years, Prof. Chen and his team have studied the PD-1/PD-L1 pathway, from cloning the molecules, identifying their function and role in the cancer setting, all leading to a development of anti-PD-1 and anti-PD-L1 therapies. Prof. Chen mentions that these therapies are used in patients when other conventional therapies failed, but he expects this cancer immunotherapy to have a broader application in the future, including early stage diseases. Recorded at the 2016 National Cancer Research Institute (NCRI) Conference in Liverpool, UK.
